How much is the latest price of a box of Gyfapisheng tablets in 2025?

Gemfapixin tablets are the world's first selective P2X3 receptor antagonist, bringing new treatment hope to patients with refractory chronic cough. This innovative drug, jointly developed by Merck and Japan's Kyorin Pharmaceuticals, inhibits the excessive cough reflex through a unique mechanism. This article will introduce in detail the latest pricing, global launch progress and necessary preparations before use of Gemfapixin tablets in 2025, providing a comprehensive reference for patients and medical professionals who are concerned about this innovative drug.

How much is the latest price of a box of Gefapisheng Tablets in 2025

As an innovative drug, the price positioning of Gefapisheng Tablets reflects the research and development costs and clinical value. The market price system in 2025 has basically taken shape.

Japanese market pricing

The price of the original drug produced by Japan's Anlin Pharmaceutical is approximately US$223 (45mg*100 tablets/box). Based on the recommended dose twice a day, the monthly treatment cost is about US$134, and the annual treatment cost is about US$1,600.

China market expectations

If it can be approved for marketing in China in 2025, it is expected to be priced higher and will cause a greater financial burden to patients in the self-pay stage before entering medical insurance.

The price positioning of Gemfapixin tablets reflects its innovative drug attributes, and patients can choose a treatment plan based on their own economic status and medical insurance policies.

Global launch status of Gemfapisant Tablets

The global registration and approval of Gyfapisyn Tablets is progressing rapidly and has been approved in many major pharmaceutical markets.

Mainly approved countries

Japan and the United States have taken the lead in approving the market, with the trade names of Lifnua and Lyfnua respectively. The EU EMA will complete the review at the end of 2024, and it will be launched in major member states such as Germany and France in early 2025.

China Approval Progress

Currently, no application for listing in China has been submitted, and the registration process is expected to start in the second half of 2025. Considering the urgent clinical need, it may be included in the priority review channel and be approved as soon as 2026.

Layout in other regions

Canada and Australia have completed technical reviews, and Asian countries such as South Korea and Singapore are conducting bridging trials. The global listing strategy adopts a step-by-step promotion model, giving priority to ensuring supply in major pharmaceutical markets.

The global launch plan of Gemfapixin tablets is steadily advancing, bringing new treatment options to patients with refractory chronic cough.

Preparation for the administration of Gefapisheng Tablets

Rational use of Gefapisheng Tablets requires adequate preparation.

Pre-medication evaluation

The cause of cough must be clarified and potential treatable diseases must be ruled out. Perform basic renal function testing (eGFR), and dose adjustment is required in patients with severe renal insufficiency. Baseline taste function was recorded for subsequent comparison.

Medicine acquisition channels

Currently, it can only be obtained through prescriptions from regular medical institutions in Japan or Europe and the United States. When purchasing medicine across borders, you need to confirm the authenticity of the medicine and check the packaging integrity and expiration date. Be wary of the risks of counterfeit drugs through illegal purchasing channels.

Treatment Monitoring Plan

Develop a regular evaluation plan for taste function, with review every 2 weeks for the first 3 months. Establish a renal function monitoring program, especially in older adults and patients with existing renal impairment. Prepare management measures for common side effects.

Adequate preparation for medication is the basis for successful treatment with Gefavixin Tablets, which needs to be implemented systematically under the guidance of professional physicians.